Talha Badar: SELECT-MDS-1 – Tamibarotene Plus Azacitidine in High-Risk MDS
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, posted on X:
“SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS.
Another PIII trial in HR-MDS didn’t meet primary endpoint of improved CR; 23.81% and 18.75% in the tamibarotene/AZA and placebo/AZA group.
mOS: tamibarotene/AZA 12.0 vs placebo/AZA group 19.4 months.
Tamibarotene: oral retinoid, targeting RARA expressing myeloid blast.”
Title: Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS
Authors: Amy E. DeZern, Sylvain Thepot, Stéphane De Botton, Andrea Patriarca, Dries Deeren, Jose Miguel Torregrose Diaz, Giovanni Marconi, Teresa Bernal del Castillo, Juan Miguel Bergua Burgues, Blanca Xicoy, Anna Jonasova, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcárcel, María Díez-Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz W. Basak, Hetty E Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A Roth, Sofia Paul, Pourab Roy, Michael Kelly, Angela Volkert, Jaime Chisolm, Tanya Abdul Malak, Virginia Klimek, Thomas Cluzeau
Read The Full Article at Blood Advances.
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023